Sugi Predict

Sugi Predict / Compounds / Pyridine

Pyridine

Pyridine

SCHEMBL16720239

C#Cc1cccc(C(=O)O)c1-n1cncn1.c1ccncc1

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.35
▸ MAPT P10636 1/20 0.33
▸ STING1 Q86WV6 1/20 0.32
▸ FAAH O00519 2/20 0.32
▸ MGLL Q99685 2/20 0.32
▸ POLB P06746 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.31
▸ GAA P10253 1/20 0.31
▸ KDM4E B2RXH2 3/20 0.30
▸ SMN1; SMN2 Q16637 2/20 0.30
▸ ADORA3 P0DMS8 1/20 0.30
▸ ADORA2A P29274 1/20 0.30
▸ ADORA1 P30542 1/20 0.30
▸ HPGD P15428 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16720215 0.89 ADORA3 (0.36) MAPTSTING1FAAHMGLLPOLB
SCHEMBL16720233 0.81 NPC1 (0.37) CYP2A6STING1POLBALDH1A1KDM4E
SCHEMBL28608913 0.81 POLB (0.41) CYP2A6MAPTSTING1FAAHMGLL
Pyridine SCHEMBL16719943 0.79 ADH5 (0.38) CYP2A6STING1GAA
SCHEMBL16720212 0.79 NPC1 (0.44) MAPTSTING1FAAHMGLLPOLB
SCHEMBL28405283 0.77 TSHR (0.46) MAPTSTING1POLBALDH1A1SMN1; SMN2
Pyridine SCHEMBL18109261 0.77 MYC (0.46) MAPTPOLBALDH1A1GAAKDM4E
SCHEMBL21816306 0.74 POLB (0.46) CYP2A6STING1MGLLPOLBALDH1A1
SCHEMBL31175286 0.74 POLB (0.46) CYP2A6STING1MGLLPOLBALDH1A1
Pyridine SCHEMBL18109257 0.74 POLB (0.40) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US claimed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP claimed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US claimed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US claimed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP claimed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO claimed
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use WISTAR INST (US) 2022-12-15 — — US disclosed
US-11242317-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2022-02-08 — — US disclosed
EP-3068758-B1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2021-09-08 — — EP disclosed
CN-105934425-B EBNA1 inhibitors and methods of use thereof 威斯塔解剖学和生物学研究所 2020-08-07 — — CN disclosed
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE WISTAR INST (US) 2020-06-11 — — US disclosed
US-10421718-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2019-09-24 — — US disclosed
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-03-29 — — US disclosed
US-9856214-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2018-01-02 — — US disclosed
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-10-06 — — US disclosed
EP-3068758-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE The Wistar Institute Of Anatomy And Biology (US) 2016-09-21 — — EP disclosed
WO-2015073864-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE THE WISAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2015-05-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CYP2A6 3151/4885MAPT 4034/4885STING1 130/4885
US-11242317-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CYP2A6 3151/4885MAPT 4034/4885STING1 130/4885
US-20160289185-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE MCM5, EBNA1BP2, MLLT1 CYP2A6 3421/4885MAPT 3498/4885STING1 74/4885
US-20200181078-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML CYP2A6 3151/4885MAPT 4034/4885STING1 130/4885
US-10421718-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML CYP2A6 3151/4885MAPT 4034/4885STING1 130/4885
US-20180086699-A1 EBNA1 INHIBITORS AND THEIR METHOD OF USE EBNA1BP2, MLLT1, PML CYP2A6 3151/4885MAPT 4034/4885STING1 130/4885
US-20220396551-A1 EBNA1 Inhibitors and Their Method of Use EBNA1BP2, MLLT1, PML CYP2A6 3151/4885MAPT 4034/4885STING1 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.